Doctors fight US company patent on umbilical cord bloodBMJ 1997; 314 doi: https://doi.org/10.1136/bmj.314.7088.1145b (Published 19 April 1997) Cite this as: BMJ 1997;314:1145
- Jacqui Wise
Doctors in Europe are fighting against the granting of a patent to a United States company for the use of blood from umbilical cords and placentas. This cord blood, which is rich in stem cells, can be used as an alternative to bone marrow transplants.
Biocyte was granted a Europe-wide patent last year by the European Patent Office in Munich for the cryopreservation of cord blood. The blood itself cannot be patented but the patent means that doctors wanting to …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial